Glaxosmithkline LLC

Jianghe Deng

Katherine L Widdowson

Xichen Lin

Jeffrey K Kerns

Christopher E Neipp

Qi Jin

Hong Nie

Jakob Busch-Petersen

Sonia M Thomas

Guoliang Lin

James Brackley, Iii

Michael Lindenmuth

Hongyi Yu

Yonghui Wang

Wei Fu

Huijie Li

Feng Wang

Gregory L Adams

Jack J Taggart

The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK&#x3b2;) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Chemical compounds

This invention relates to novel compounds, compositions and combinations thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

IL-8 receptor antagonists

Growing community of inventors

King of Prussia, PA, United States of America

Jianghe Deng